Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IMpower131

Roche Basel Switzerland

Roche presents new data in NMOSD, could challenge Alexion’s Soliris

Reduced risk of relapse by 55%

AstraZeneca AZ

Can AZ’s Imfinzi challenge Tecentriq in small cell lung cancer?

New data shows improvement in overall survival

- PMLiVE

Amgen reveals more data on KRAS drug

Unveiled an overall disease control rate of 100%

Roche Basel Switzerland

Roche scores EU approval twice for Tecentriq in lung cancer

Carves out space in a market dominated by MSD's Keytruda

- PMLiVE

Genentech agrees trade secret theft settlement with Taiwan’s JHL

Three ex-Genetech workers pleaded not guilty to criminal theft charges

Roche Basel Switzerland

Roche’s flu drug Xofluza scores phase 3 primary endpoint

Demonstrates efficacy as a preventative treatment

- PMLiVE

Novartis scores promising phase 3 MS study

Takes fight to Roche’s blockbuster ocrevus

- PMLiVE

Tecentriq approved in Europe for triple negative breast cancer

Roche can dominate in niche setting

- PMLiVE

‘Therapeutic overcrowding’ could hit big pharma returns

Jefferies analysts identify most at-risk companies

- PMLiVE

AZ’s Imfinzi combo bombs again in non-small cell lung cancer

Ends AZ’s main challenge to Keytruda for first-line use

- PMLiVE

Roche’s Hemlibra scores broader NHS funding

Expands to around 2,000 patients in England

- PMLiVE

Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO

Garraway joins from Eli Lilly

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links